Enoksaparin-Pharmex solution for infection. 10000 Anti-ha ME/ml fl. 3 ml No. 1

Solution for injections of Enoksaparin-Pharmex is shown for use by the adult:

• for prevention of venous tromboembolic episodes at surgical patients with moderate and high risk, especially at the patients who are subject to orthopedic or all-surgical surgeries, including surgeries concerning oncological diseases;
• for prevention of venous tromboembolic episodes at therapeutic patients with acute diseases (such as acute heart failure, respiratory insufficiency, heavy infections or rheumatic diseases) and the lowered mobility which have the increased risk of developing of a venous thrombembolia;
• for treatment of the deep vein thrombosis (DVT) and a pulmonary embolism (TELA), except for cases of TELA at which performing thrombolytic therapy or surgical intervention can be required;
• for prevention of formation of blood clots in extracorporal blood circulation during a hemodialysis;
• at a sharp coronary syndrome:
  • for treatment of unstable stenocardia and a myocardial infarction without raising of a ST (NSTEMI) segment, in combination with oral administration of acetylsalicylic acid;
  • for treatment of an acute myocardial infarction with raising of a ST (STEMI) segment, including at patients to whom medicament treatment or the further percutaneous coronary intervention (PCI) is planned.

Structure

Active ingredient: enoksaparin;

1 ml 10000 Anti-ha ME that is equivalent to 100 mg of an enoksaparin of sodium;

Excipients: benzyl alcohol, water for injections.

Contraindication

Enoksaparin of sodium is contraindicated to use to patients with such states:

• hypersensitivity to a sodium enoksaparin, heparin or its derivatives, including other low-molecular heparins;
• existence in the anamnesis of the immunomediated geparinindutsirovanny thrombocytopenia (GIT) within the last 100 days in the presence of the circulating antibodies;
• active clinically significant bleeding and states with high risk of developing of bleeding, including recently had hemorrhagic stroke, a digestive tract ulcer, presence of a malignant new growth with high risk of bleeding, recently postponed surgery on a brain, a spinal cord or eyes, the known or suspected gullet varicosity, arteriovenous malformation, vascular aneurysms or serious malformations of intraspinal or intratserebralny vessels;
• spinal or epidural anesthesia or lokoregionarny anesthesia if enoksaparin sodium it was used for treatment within the last 24 hours.

Route of administration

Way of introduction - hypodermic (except for patients with a myocardial infarction with an elevation of a segment of ST which need intravenous bolyusny administration).

It is recommended for use by the adult.

should not administer the Drug intramusculary.

1 ml of solution for injections about 10000 Anti-ha.

Feature of use

pregnant only in case of establishment by the doctor of the accurate need for such treatment.

to

Children

It is contraindicated.

Drivers

Influence of an enoksaparin of sodium on ability to run vehicles and to work with other mechanisms is absent or is insignificant.

Overdose

Symptoms. Inadvertent overdoses of an enoksaparin of sodium as a result in/in, extracorporal or p / to introduction can give to hemorrhagic complications. After reception even enough high doses absorption of an enoksaparin of sodium is improbable.

Treatment. Anticoagulating effects of medicament can be substantially neutralized slow in/in administration of protamin. The dose of protamin depends on the entered dose of an enoksaparin of sodium:

• 1 mg of protamin the anticoagulating effect 100 ME (1 mg) neutralizes an enoksaparin of sodium if enoksaparin sodium it was entered within the last 8 hours.
• Can use infusional administration of protamin in a dose of 0.5 mg on everyone 100 ME (1 mg) an enoksaparina of sodium if enoksaparin sodium it was entered in more than 8 hours to use of protamin or if need of purpose of the second dose of protamin was defined.
can be
• In 12 hours after introduction of an enoksaparin of sodium of use of protamin not necessary.

fully (at most approximately for 60%) (see Instructions for use of protaminovy salts).

Side effects

In clinical trials by undesirable reactions about which it was reported most often were the hemorrhagic phenomena, thrombocytopenia and a thrombocytosis.

Subcutaneous injection - not to mix

with other medicines.

Storage conditions

to Store

in original packing at a temperature not above 25 °C. Not to freeze.

to Store

out of children's reach.

Expiration date - 2 years.